Patents by Inventor Robert M. Ratcliffe

Robert M. Ratcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5955449
    Abstract: Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: September 21, 1999
    Assignee: SYNSORB Biotech Inc.
    Inventors: Glen D. Armstrong, Robert M. Ratcliffe
  • Patent number: 5753631
    Abstract: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: May 19, 1998
    Assignee: Cytel Corporation
    Inventors: James C. Paulson, Mary S. Perez, Federico C. A. Gaeta, Robert M. Ratcliffe
  • Patent number: 5679653
    Abstract: Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 21, 1997
    Assignee: Synsorb Biotech Inc.
    Inventors: Glen D. Armstrong, Robert M. Ratcliffe
  • Patent number: 5620902
    Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the .alpha. anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: April 15, 1997
    Assignee: Alberta Research Council
    Inventors: Robert M. Ratcliffe, Andre P. Venot, S. Zaheer Abbas
  • Patent number: 5620858
    Abstract: Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT).
    Type: Grant
    Filed: September 27, 1993
    Date of Patent: April 15, 1997
    Assignee: Synsorb Biotech Inc.
    Inventors: Glen D. Armstrong, Robert M. Ratcliffe
  • Patent number: 5576305
    Abstract: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 19, 1996
    Assignee: Cytel Corporation
    Inventor: Robert M. Ratcliffe
  • Patent number: 5527901
    Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the .alpha. anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.
    Type: Grant
    Filed: December 22, 1993
    Date of Patent: June 18, 1996
    Assignee: Alberta Research Council
    Inventors: Robert M. Ratcliffe, Andre P. Venot, S. Zaheer Abbas
  • Patent number: 5344870
    Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the .alpha. anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.
    Type: Grant
    Filed: March 17, 1992
    Date of Patent: September 6, 1994
    Assignee: Alberta Research Council
    Inventors: Robert M. Ratcliffe, Andre P. Venot
  • Patent number: 5296594
    Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the a anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.
    Type: Grant
    Filed: June 28, 1990
    Date of Patent: March 22, 1994
    Assignee: Alberta Research Council
    Inventors: Robert M. Ratcliffe, Andre P. Venot, S. Zaheer Abbas
  • Patent number: 5079353
    Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an a (2-3) or a (2-6) linkage is controlled to favor the a anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate a (2-3) and a (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.
    Type: Grant
    Filed: December 2, 1987
    Date of Patent: January 7, 1992
    Assignee: Chembiomed, Ltd.
    Inventors: Robert M. Ratcliffe, Andre P. Venot
  • Patent number: 4866041
    Abstract: Processes are provided for the syntheses of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artificial T-antigens, and to insoluble supports to form T-immunoadsorbents. The artifical T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.
    Type: Grant
    Filed: September 1, 1988
    Date of Patent: September 12, 1989
    Assignee: Chembiomed, Ltd.
    Inventors: Raymond U. Lemieux, Robert M. Ratcliffe, Donald A. Baker
  • Patent number: 4855126
    Abstract: Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artificial T-antigens, and to insoluble supports to form T-immunoadsorbents. The artificial T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.
    Type: Grant
    Filed: August 17, 1987
    Date of Patent: August 8, 1989
    Assignee: Chembiomed Ltd.
    Inventors: Raymond U. Lemieuz, Robert M. Ratcliffe, Donald A. Baker
  • Patent number: 4794176
    Abstract: Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artifical T-antigens, and to insoluble supports to form T-immunoadsorbents. The artificial T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.
    Type: Grant
    Filed: October 15, 1986
    Date of Patent: December 27, 1988
    Assignee: Chembiomed
    Inventors: Raymond U. Lemieux, Robert M. Ratcliffe, Donald A. Baker
  • Patent number: 4767845
    Abstract: Processes are provided for the synthesis of the human T-antigenic determinant 2-acetamido-2-deoxy-3-O-(.beta.-D-galactopyranosyl)-.alpha.-D-galactopyran oside containing an .alpha.-O-glycosidically linked bridging arm O--(CH.sub.2).sub.n COR. The determinant is coupled to carrier molecules to form artificial T-antigens, and to insoluble supports to form T-immunoadsorbents. The artifical T-antigen is shown to elicit a delayed type hypersensitivity reaction as a diagnostic for the presence of cancer in humans.
    Type: Grant
    Filed: August 17, 1987
    Date of Patent: August 30, 1988
    Assignee: Chembiomed, Ltd.
    Inventors: Raymond U. Lemieux, Robert M. Ratcliffe, Donald A. Baker